Bruce Benedick, MD
Interventional Cardiology · East Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 5 carriers
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Memorial Medical Center · Mills-Peninsula Medical Center · Sequoia Hospital · Stanford Health Care · Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plans that list them
18 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Benedick’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G65711 · Current
Licensed to practise in California · since 1989 · expires 2027-03-31 · University of Utah School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Memorial Medical CenterModesto, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.093, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for Memorial Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.093 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.41 to 2.2) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.75 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.77 (144.66 to 226.88) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.1 · 194 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 513 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 640 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 4,882 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.42) · 10,183 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 10,422 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.4 (1.58 to 5.23) · 2,596 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.92 (0.45 to 3.38) · 845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.1 (1.78 to 4.42) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.71 (5.69 to 17.72) · 885 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.28 (3.75 to 10.81) · 829 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.72) · 9,080 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 283 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.389 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.485 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.507 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 255 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 849 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 19.2 · 201 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.4 · 584 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.6 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 895 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.3 to 6.9) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 273 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 341 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (10.2 to 16.1) · 2,334 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 717 cases | No different | Jan 2024 – Dec 2024 |
What patients said (655 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$822,988
Medicare paid this office $822,988 for 1,846 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 821 | $171,899 | $155 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 106 | $161,079 | $1,520 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 746 | $146,828 | $189 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 106 | $86,959 | $410 |
| Return visit (30+ min) | 458 | $58,855 | $122 |
See all 27 services
| Long return visit (40+ min) | 821 | $171,899 | $155 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 106 | $161,079 | $1,520 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 746 | $146,828 | $189 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 106 | $86,959 | $410 |
| Return visit (30+ min) | 458 | $58,855 | $122 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 188 | $40,074 | $213 |
| New patient visit (60+ min) | 171 | $34,646 | $203 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 820 | $14,959 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 632 | $11,975 | $12 |
| Programming of dual lead pacemaker system | 70 | $9,710 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $9,577 | $103 |
| 3d radiographic procedure | 299 | $7,939 | $26 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 35 | $7,001 | $194 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 100 | $6,991 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $5,569 | $143 |
| Injection, regadenoson, 0.1 mg | 107 | $2,798 | None |
| Heart muscle strain imaging | 69 | $2,779 | $39 |
| Evaluation of implantable heart and blood vessel monitoring system | 31 | $2,765 | $46 |
| Programming of multiple lead pacemaker system | 20 | $2,666 | $78 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 119 | $2,618 | $21 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 122 | $2,460 | $19 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 123 | $1,514 | $12 |
| Short return visit (20+ min) | 14 | $1,404 | $83 |
| Heart rhythm recording of continous external ekg over 8-15 days | 115 | $1,391 | $12 |
| External shock to heart to regulate heart beat | 14 | $1,356 | $97 |
| Programming of single lead pacemaker system | 14 | $1,048 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 15 | $781 | $52 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 1-10 | None |
| Varicose vein removal | 1-10 | None |
Who their Medicare patients are
1,846 Original Medicare patients in 2024. Average age 79 · Under 65 1% · 85 and older 23% · Women 43% · Also on Medicaid 3% · Health risk score 1.13. At or below the middle of the specialty; the typical interventional cardiology clinician is at 1.7.
Conditions among them: High blood pressure 75% · Coronary heart disease 51% · Atrial fibrillation 43% · Chronic kidney disease 25% · Diabetes 24% · Heart failure 22% · Cancer 19% · Depression 11% · COPD 10% · Stroke 9% · Dementia 5%.
The office billed $3,767,168, Medicare allowed $1,080,497 and paid $822,988; for 7,052 services of 59 kinds; $2,798 of it was for drugs given in the office and $820,190 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,846 | 7,052 | 79 | 1.13 | $3,767,168 | $822,988 |
| 2023 | 1,856 | 5,923 | 79 | 1.14 | $3,581,544 | $860,233 |
| 2022 | 1,718 | 6,079 | 78 | 1.12 | $3,297,530 | $826,031 |
| 2021 | 1,458 | 6,244 | 78 | 1.15 | $3,440,517 | $889,801 |
| 2020 | 976 | 6,222 | 78 | 1.31 | $2,957,685 | $752,827 |
| 2019 | 1,062 | 7,291 | 78 | 1.30 | $3,749,685 | $900,686 |
| 2018 | 1,104 | 7,139 | 78 | 1.35 | $3,243,091 | $788,221 |
| 2017 | 1,047 | 6,785 | 78 | 1.37 | $3,400,618 | $802,276 |
| 2016 | 1,013 | 6,537 | 79 | 1.39 | $3,242,772 | $769,550 |
| 2015 | 975 | 6,548 | 79 | 1.46 | $3,627,177 | $902,671 |
| 2014 | 969 | 6,603 | 78 | 1.32 | $3,336,960 | $973,761 |
| 2013 | 1,005 | 6,727 | 79 | 1.42 | $3,021,159 | $847,735 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 28 services
| Long return visit (40+ min) | 943 | $252,224 | $158 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 108 | $166,454 | $1,541 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 677 | $133,757 | $192 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 108 | $90,159 | $417 |
| New patient visit (60+ min) | 187 | $37,854 | $202 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 162 | $37,699 | $231 |
| Injection, regadenoson, 0.1 mg | 111 | $18,723 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $15,360 | $107 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 637 | $12,404 | $13 |
| Programming of dual lead pacemaker system | 69 | $9,982 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,268 | $148 |
| 3d radiographic procedure | 222 | $5,744 | $25 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 27 | $5,466 | $188 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 75 | $5,135 | $68 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 18 | $3,612 | $201 |
| Evaluation of implantable heart and blood vessel monitoring system | 32 | $3,004 | $47 |
| Programming of multiple lead pacemaker system | 20 | $2,925 | $81 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 123 | $2,642 | $21 |
| Return visit (30+ min) | 24 | $1,955 | $81 |
| Heart muscle strain imaging | 45 | $1,835 | $39 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 124 | $1,548 | $12 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 60 | $1,452 | $23 |
| External shock to heart to regulate heart beat | 14 | $1,386 | $99 |
| Short return visit (20+ min) | 15 | $1,349 | $71 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 16 | $987 | $62 |
| Heart rhythm recording of continous external ekg over 8-15 days | 60 | $802 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $307 | $26 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $260 | $11 |
2022: 33 services
| Long return visit (40+ min) | 908 | $253,199 | $157 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 97 | $149,743 | $1,544 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 637 | $125,088 | $186 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 98 | $81,045 | $418 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 134 | $29,572 | $219 |
| New patient visit (60+ min) | 146 | $29,513 | $202 |
| Injection, regadenoson, 0.1 mg | 99 | $19,196 | None |
| Programming of dual lead pacemaker system | 73 | $12,300 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $11,428 | $91 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 562 | $10,203 | $12 |
| Return visit (30+ min) | 68 | $7,680 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,047 | $172 |
| 3d radiographic procedure | 244 | $5,901 | $23 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 26 | $5,049 | $194 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 22 | $4,445 | $202 |
| Programming of multiple lead pacemaker system | 20 | $3,791 | $81 |
| Evaluation of implantable heart and blood vessel monitoring system | 32 | $3,666 | $48 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 52 | $3,540 | $68 |
| Short return visit (20+ min) | 26 | $2,725 | $74 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 103 | $2,336 | $22 |
| Heart muscle strain imaging | 51 | $2,180 | $40 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 95 | $1,953 | $20 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,727 | $96 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 67 | $1,655 | $24 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 103 | $1,499 | $14 |
| Programming of single lead pacemaker system | 12 | $1,472 | $64 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 31 | $1,180 | $23 |
| 3d radiographic procedure with computerized image postprocessing | 15 | $1,167 | $73 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 27 | $1,146 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 67 | $999 | $14 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 12 | $875 | $24 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 12 | $762 | $63 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $319 | $11 |
2021: 35 services
| Long return visit (40+ min) | 735 | $226,061 | $161 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 121 | $194,122 | $1,578 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 561 | $115,810 | $191 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 121 | $102,710 | $418 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 117 | $26,090 | $219 |
| Return visit (30+ min) | 231 | $26,037 | $99 |
| Injection, regadenoson, 0.1 mg | 123 | $24,000 | None |
| New patient visit (60+ min) | 86 | $17,070 | $198 |
| Programming of dual lead pacemaker system | 64 | $12,401 | $76 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 623 | $11,101 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $11,006 | $93 |
| 3d radiographic procedure with computerized image postprocessing | 132 | $9,720 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,540 | $178 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 108 | $7,456 | $68 |
| New patient visit (45+ min) | 45 | $6,427 | $143 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 33 | $5,889 | $178 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 21 | $3,838 | $183 |
| Evaluation of implantable heart and blood vessel monitoring system | 32 | $3,733 | $45 |
| Programming of multiple lead pacemaker system | 14 | $3,405 | $81 |
| Programming of multiple lead implantable defibrillator system | 15 | $2,709 | $100 |
| Short return visit (20+ min) | 20 | $2,561 | $78 |
| 3d radiographic procedure | 94 | $2,163 | $23 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 14 | $2,061 | $129 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 68 | $1,610 | $23 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 75 | $1,583 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 30 | $1,542 | $24 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 22 | $1,415 | $64 |
| External shock to heart to regulate heart beat | 14 | $1,371 | $98 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,363 | $97 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 27 | $1,356 | $24 |
| Heart muscle strain imaging | 30 | $1,258 | $42 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 75 | $1,050 | $14 |
| Heart rhythm recording of continous external ekg over 8-15 days | 64 | $936 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 37 | $859 | $23 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 25 | $280 | $11 |
2020: 30 services
| Long return visit (40+ min) | 787 | $195,561 | $128 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 104 | $168,384 | $1,619 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 448 | $96,181 | $202 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 104 | $87,194 | $419 |
| Injection, regadenoson, 0.1 mg | 108 | $20,264 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 731 | $19,168 | $15 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 83 | $18,221 | $217 |
| New patient visit (60+ min) | 82 | $15,633 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $13,886 | $95 |
| Programming of dual lead pacemaker system | 60 | $9,104 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,715 | $185 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 110 | $7,601 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 63 | $7,528 | $94 |
| Return visit (30+ min) | 57 | $6,078 | $89 |
| 3d radiographic procedure | 187 | $4,697 | $23 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 21 | $4,474 | $195 |
| External ekg recording for more than 48 hours up to 21 days | 136 | $4,143 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 136 | $3,683 | $24 |
| Evaluation of implantable heart and blood vessel monitoring system | 34 | $3,555 | $41 |
| Programming of multiple lead implantable defibrillator system | 15 | $3,082 | $93 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $2,633 | $188 |
| Programming of multiple lead pacemaker system | 15 | $2,575 | $72 |
| Short return visit (20+ min) | 18 | $1,477 | $64 |
| External shock to heart to regulate heart beat | 13 | $1,340 | $103 |
| Ultrasound of heart blood flow, valves and chambers | 24 | $1,305 | $54 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 76 | $1,064 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 28 | $760 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 16 | $464 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $340 | $26 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $190 | $11 |
2019: 33 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 146 | $228,155 | $1,531 |
| Long return visit (40+ min) | 800 | $192,974 | $123 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 146 | $123,245 | $414 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 416 | $89,404 | $205 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 134 | $30,996 | $230 |
| Injection, regadenoson, 0.1 mg | 148 | $27,575 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 811 | $22,321 | $15 |
| New patient visit (60+ min) | 119 | $20,942 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 82 | $18,273 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 152 | $10,694 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,935 | $182 |
| Programming of dual lead pacemaker system | 59 | $8,013 | $60 |
| Ultrasound of heart blood flow, valves and chambers | 134 | $7,372 | $55 |
| 3d radiographic procedure | 312 | $7,351 | $23 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 37 | $7,201 | $195 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 13 | $6,593 | $507 |
| Return visit (30+ min) | 50 | $5,912 | $99 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 25 | $4,689 | $188 |
| Evaluation of implantable heart and blood vessel monitoring system | 39 | $4,362 | $36 |
| Programming of multiple lead pacemaker system | 18 | $4,117 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 137 | $3,676 | $26 |
| Short return visit (20+ min) | 31 | $2,980 | $65 |
| External ekg recording for more than 48 hours up to 21 days | 107 | $2,966 | $26 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 14 | $2,644 | $126 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 107 | $2,642 | $23 |
| Programming of multiple lead implantable defibrillator system | 13 | $2,465 | $85 |
| Programming of dual lead implantable defibrillator system | 13 | $1,649 | $79 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,547 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,508 | $66 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 97 | $1,422 | $6 |
| External shock to heart to regulate heart beat | 12 | $1,419 | $101 |
| Programming of single lead pacemaker system | 11 | $902 | $50 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 42 | $463 | $11 |
2018: 36 services
| Long return visit (40+ min) | 796 | $198,657 | $125 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 93 | $138,959 | $1,494 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 424 | $91,822 | $197 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 91 | $72,094 | $396 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 152 | $34,083 | $221 |
| New patient visit (60+ min) | 145 | $26,312 | $181 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 11 | $24,474 | $1,530 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 847 | $24,200 | $15 |
| Injection, regadenoson, 0.1 mg | 106 | $18,798 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $17,416 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 24 | $12,121 | $505 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,982 | $180 |
| Ultrasound of heart blood flow, valves and chambers | 152 | $8,361 | $54 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 39 | $7,757 | $199 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 115 | $7,610 | $66 |
| 3d radiographic procedure | 281 | $6,878 | $23 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 33 | $6,509 | $197 |
| Programming of dual lead pacemaker system | 58 | $6,427 | $52 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $5,781 | $482 |
| Return visit (30+ min) | 61 | $5,181 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 155 | $4,233 | $27 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 24 | $4,181 | $87 |
| Programming of multiple lead implantable defibrillator system | 14 | $3,412 | $78 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 19 | $3,403 | $110 |
| Short return visit (20+ min) | 40 | $3,343 | $62 |
| Evaluation of implantable heart and blood vessel monitoring system | 38 | $3,189 | $31 |
| External ekg recording for more than 48 hours up to 21 days | 96 | $2,836 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 97 | $2,523 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,458 | $65 |
| Programming of multiple lead pacemaker system | 13 | $1,867 | $57 |
| Programming of single lead pacemaker system | 14 | $1,753 | $45 |
| Emergency department visit with high level of medical decision making | 11 | $1,621 | $147 |
| External shock to heart to regulate heart beat | 14 | $1,496 | $100 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 104 | $1,466 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 21 | $1,318 | $63 |
| Programming of dual lead implantable defibrillator system | 11 | $1,125 | $66 |
2017: 33 services
| Long return visit (40+ min) | 767 | $174,570 | $120 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 108 | $158,893 | $1,471 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 402 | $97,497 | $229 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 20 | $53,145 | $1,563 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 108 | $49,194 | $230 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 159 | $43,822 | $274 |
| New patient visit (60+ min) | 137 | $24,694 | $180 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 785 | $21,958 | $15 |
| Injection, regadenoson, 0.1 mg | 110 | $18,994 | None |
| 3d radiographic procedure with computerized image postprocessing | 263 | $18,665 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 90 | $15,903 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,198 | $180 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 17 | $9,087 | $478 |
| Ultrasound of heart blood flow, valves and chambers | 159 | $8,756 | $55 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 110 | $8,067 | $73 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 40 | $7,990 | $195 |
| Return visit (30+ min) | 70 | $6,861 | $98 |
| Programming of dual lead pacemaker system | 60 | $6,040 | $53 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 27 | $5,711 | $122 |
| 3d radiographic procedure | 206 | $4,920 | $23 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 27 | $4,867 | $174 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 159 | $4,272 | $27 |
| Short return visit (20+ min) | 50 | $4,136 | $66 |
| External ekg recording for more than 48 hours up to 21 days | 98 | $2,846 | $27 |
| Programming of multiple lead implantable defibrillator system | 14 | $2,680 | $84 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 98 | $2,531 | $24 |
| Evaluation of implantable heart and blood vessel monitoring system | 34 | $2,172 | $27 |
| External shock to heart to regulate heart beat | 15 | $1,867 | $98 |
| Programming of multiple lead pacemaker system | 14 | $1,825 | $63 |
| Programming of dual lead implantable defibrillator system | 16 | $1,696 | $74 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $1,377 | $57 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 121 | $1,345 | $6 |
| Programming of single lead pacemaker system | 11 | $1,206 | $46 |
2016: 37 services
| Long return visit (40+ min) | 705 | $161,257 | $121 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 94 | $138,574 | $1,459 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 387 | $92,070 | $228 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 25 | $62,999 | $1,575 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 94 | $42,356 | $227 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 121 | $32,942 | $272 |
| 3d radiographic procedure with computerized image postprocessing | 374 | $26,520 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 742 | $20,329 | $15 |
| New patient visit (60+ min) | 109 | $19,334 | $177 |
| Injection, regadenoson, 0.1 mg | 97 | $16,567 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $15,707 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $13,611 | $177 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 50 | $9,966 | $188 |
| Return visit (30+ min) | 101 | $9,228 | $80 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 100 | $7,302 | $72 |
| Programming of dual lead pacemaker system | 60 | $6,727 | $52 |
| Ultrasound of heart blood flow, valves and chambers | 121 | $6,585 | $54 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 36 | $6,475 | $122 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 29 | $5,909 | $204 |
| Short return visit (20+ min) | 47 | $4,470 | $64 |
| Critical care, first 30-74 minutes | 14 | $4,216 | $192 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 120 | $3,193 | $27 |
| Programming of multiple lead implantable defibrillator system | 17 | $2,411 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,396 | $63 |
| Programming of multiple lead pacemaker system | 15 | $2,383 | $63 |
| External ekg recording for more than 48 hours up to 21 days | 80 | $1,953 | $24 |
| Programming of single lead pacemaker system | 13 | $1,921 | $46 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 79 | $1,816 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $1,740 | $56 |
| Evaluation of implantable heart and blood vessel monitoring system | 32 | $1,724 | $27 |
| 3d radiographic procedure | 71 | $1,613 | $22 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 135 | $1,611 | $6 |
| External shock to heart to regulate heart beat | 11 | $1,288 | $107 |
| Programming of dual lead implantable defibrillator system | 11 | $1,258 | $74 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,242 | $96 |
| Return visit (30+ min) | 16 | $1,099 | $69 |
| Hospital discharge day management, 30 minutes or less | 11 | $710 | $65 |
2015: 39 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 119 | $181,419 | $1,512 |
| Long return visit (40+ min) | 699 | $176,679 | $131 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 34 | $102,595 | $1,682 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 382 | $98,104 | $245 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 114 | $54,617 | $240 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 115 | $33,855 | $289 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 685 | $21,108 | $17 |
| Injection, regadenoson, 0.1 mg | 117 | $19,464 | None |
| 3d radiographic procedure with computerized image postprocessing | 285 | $19,317 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $19,040 | $98 |
| New patient visit (60+ min) | 98 | $18,072 | $184 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 65 | $14,452 | $213 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 66 | $13,493 | $190 |
| Return visit (30+ min) | 91 | $10,735 | $101 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 117 | $9,119 | $77 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 15 | $8,673 | $510 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 37 | $7,178 | $133 |
| Ultrasound of heart blood flow, valves and chambers | 115 | $6,837 | $58 |
| Programming of dual lead pacemaker system | 55 | $6,537 | $57 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 26 | $5,350 | $206 |
| Programming of multiple lead implantable defibrillator system | 14 | $3,995 | $89 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 12 | $3,891 | $324 |
| Destruction of subsequent incompetent veins of arm or leg using radiofrequency and imaging guidance | 12 | $3,643 | $304 |
| Short return visit (20+ min) | 41 | $3,549 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $3,395 | $68 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 115 | $3,364 | $29 |
| 3d radiographic procedure | 129 | $3,013 | $23 |
| External ekg recording for more than 48 hours up to 21 days with analysis, report, review and interpretation | 25 | $2,422 | $97 |
| Initial hospital observation care per day, typically 70 minutes | 13 | $2,267 | $174 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 36 | $2,154 | $60 |
| Evaluation of implantable heart and blood vessel monitoring system | 30 | $2,034 | $28 |
| External shock to heart to regulate heart beat | 16 | $1,993 | $117 |
| Programming of multiple lead pacemaker system | 14 | $1,977 | $66 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 142 | $1,759 | $7 |
| Programming of dual lead implantable defibrillator system | 11 | $1,410 | $78 |
| External ekg recording for more than 48 hours up to 21 days | 45 | $1,303 | $28 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 14 | $1,200 | $86 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 45 | $1,165 | $25 |
| Return visit (30+ min) | 13 | $958 | $74 |
2014: 36 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 142 | $210,118 | $1,480 |
| Long return visit (40+ min) | 681 | $165,330 | $123 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 37 | $116,819 | $1,718 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 414 | $102,211 | $231 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 142 | $64,078 | $229 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 56 | $40,514 | $711 |
| 3d radiographic procedure with computerized image postprocessing | 415 | $35,885 | $82 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 87 | $24,451 | $278 |
| Injection, regadenoson, 0.1 mg | 145 | $23,990 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 123 | $21,333 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 665 | $18,779 | $15 |
| New patient visit (60+ min) | 93 | $16,664 | $179 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 67 | $12,609 | $188 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 148 | $10,620 | $72 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 16 | $8,789 | $463 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 42 | $7,831 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,301 | $180 |
| Programming of dual lead pacemaker system | 55 | $5,873 | $53 |
| Short return visit (20+ min) | 61 | $5,296 | $62 |
| Critical care, first 30-74 minutes | 16 | $5,277 | $195 |
| Ultrasound of heart blood flow, valves and chambers | 86 | $4,731 | $54 |
| Return visit (30+ min) | 51 | $4,608 | $87 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 23 | $4,348 | $189 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 12 | $3,702 | $309 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,590 | $64 |
| Programming of multiple lead implantable defibrillator system | 14 | $3,220 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 49 | $2,772 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 86 | $2,338 | $27 |
| Programming of dual lead implantable defibrillator system | 14 | $2,008 | $74 |
| Programming of multiple lead pacemaker system | 12 | $1,885 | $63 |
| Evaluation of implantable heart and blood vessel monitoring system | 29 | $1,804 | $27 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 56 | $1,333 | $23 |
| External shock to heart to regulate heart beat | 11 | $1,201 | $109 |
| 3d radiographic procedure | 38 | $1,098 | $29 |
| Return visit (30+ min) | 16 | $1,050 | $66 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 80 | $929 | $6 |
2013: 39 services
| Long return visit (40+ min) | 678 | $164,552 | $122 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 118 | $140,156 | $1,188 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 421 | $83,575 | $189 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 84 | $67,499 | $785 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 20 | $62,360 | $1,834 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 118 | $53,772 | $228 |
| 3d radiographic procedure with computerized image postprocessing | 433 | $36,787 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 177 | $28,520 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 660 | $21,067 | $17 |
| Injection, regadenoson, 0.1 mg | 120 | $20,010 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 84 | $18,772 | $223 |
| New patient visit (60+ min) | 73 | $12,614 | $173 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 126 | $9,576 | $76 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 49 | $9,494 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,513 | $170 |
| Critical care, first 30-74 minutes | 25 | $7,998 | $190 |
| Programming of dual lead pacemaker system | 67 | $7,933 | $52 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 22 | $6,868 | $312 |
| Short return visit (20+ min) | 78 | $5,941 | $59 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 24 | $4,645 | $119 |
| Return visit (30+ min) | 39 | $3,800 | $95 |
| Transitional care management services for problem of high complexity | 17 | $3,718 | $219 |
| Ultrasound of heart blood flow, valves and chambers | 84 | $3,646 | $43 |
| Programming of multiple lead implantable defibrillator system | 14 | $3,216 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,006 | $63 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 15 | $2,923 | $195 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $2,217 | $55 |
| Programming of multiple lead pacemaker system | 12 | $2,083 | $61 |
| Evaluation of implantable heart and blood vessel monitoring system | 26 | $2,005 | $26 |
| External shock to heart to regulate heart beat | 17 | $1,932 | $107 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,901 | $95 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 84 | $1,870 | $22 |
| Programming of dual lead implantable defibrillator system | 12 | $1,711 | $71 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 84 | $1,676 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 18 | $1,434 | $80 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 119 | $1,431 | $6 |
| Return visit (30+ min) | 21 | $1,430 | $68 |
| Programming of single lead pacemaker system | 11 | $1,112 | $46 |
| Hospital discharge day management, 30 minutes or less | 12 | $770 | $64 |
Drugs they prescribed that Part D paid
$2,570,293
Pharmacies billed $2,570,293 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 9,697) in 2024. At or below the middle of the specialty; the typical interventional cardiology clinician is at 0%.
7,968 generic and 1,729 brand-name prescriptions · $2,570,293 in drug cost · 26 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 630 | $937,040 | $1,487 |
| Jardiance | 529 | $790,532 | $1,494 |
| Entresto | 169 | $279,632 | $1,655 |
| Repatha Sureclick | 101 | $137,257 | $1,359 |
| Multaq | 39 | $66,679 | $1,710 |
See all 55 drugs
| Eliquis | 630 | $937,040 | $1,487 |
| Jardiance | 529 | $790,532 | $1,494 |
| Entresto | 169 | $279,632 | $1,655 |
| Repatha Sureclick | 101 | $137,257 | $1,359 |
| Multaq | 39 | $66,679 | $1,710 |
| Xarelto | 47 | $62,068 | $1,321 |
| Praluent | 51 | $48,740 | $956 |
| Ezetimibe | 807 | $31,918 | $40 |
| Vascepa | 19 | $16,612 | $874 |
| Atorvastatin | 1,395 | $15,840 | $11 |
| Losartan | 1,369 | $15,151 | $11 |
| Farxiga | 11 | $12,987 | $1,181 |
| Rosuvastatin | 412 | $7,984 | $19 |
| Carvedilol | 499 | $7,087 | $14 |
| Amlodipine Besylate | 814 | $5,732 | $7 |
| Dofetilide | 15 | $5,384 | $359 |
| Eplerenone | 60 | $5,166 | $86 |
| Spironolactone | 438 | $5,162 | $12 |
| Metoprolol | 274 | $3,958 | $14 |
| Diltiazem 24hr Er (Cd) | 79 | $2,869 | $36 |
| Spironolactone-Hctz | 67 | $2,782 | $42 |
| Pravastatin | 117 | $2,448 | $21 |
| Lisinopril | 156 | $1,521 | $10 |
| Clopidogrel | 108 | $1,503 | $14 |
| Hydrochlorothiazide | 270 | $1,460 | $5 |
| Olmesartan-Hydrochlorothiazide | 13 | $1,342 | $103 |
| Midodrine | 13 | $1,316 | $101 |
| Furosemide | 154 | $1,137 | $7 |
| Levothyroxine | 73 | $1,125 | $15 |
| Olmesartan Medoxomil | 47 | $1,084 | $23 |
| Amiodarone | 56 | $1,082 | $19 |
| Valsartan | 54 | $975 | $18 |
| Simvastatin | 74 | $885 | $12 |
| Synthroid | 13 | $868 | $67 |
| Propafenone | 11 | $789 | $72 |
| Metformin Hcl Er | 43 | $688 | $16 |
| Irbesartan | 58 | $648 | $11 |
| Losartan-Hydrochlorothiazide | 29 | $623 | $21 |
| Candesartan Cilexetil | 11 | $607 | $55 |
| Sotalol | 32 | $460 | $14 |
| Flecainide Acetate | 13 | $442 | $34 |
| Valsartan-Hydrochlorothiazide | 18 | $428 | $24 |
| Nitroglycerin | 18 | $417 | $23 |
| Digoxin | 20 | $387 | $19 |
| Telmisartan | 11 | $364 | $33 |
| Allopurinol | 30 | $332 | $11 |
| Enalapril Maleate | 12 | $273 | $23 |
| Torsemide | 12 | $214 | $18 |
| Potassium Chloride | 11 | $208 | $19 |
| Atenolol | 15 | $199 | $13 |
| Metformin | 28 | $178 | $6 |
| Sotalol Af | 13 | $168 | $13 |
| Benazepril | 19 | $104 | $5 |
| Omeprazole | 11 | $60 | $5 |
| Ampicillin Trihydrate | 11 | $59 | $5 |
Year by year
| 2024 | 9,697 | 1,081 | 0% (0) | 18% | $2,570,293 |
| 2023 | 9,506 | 1,046 | 0% (0) | 18% | $2,612,662 |
| 2022 | 8,365 | 958 | 0% (0) | 17% | $2,039,847 |
| 2021 | 7,714 | 822 | 0% (0) | 17% | $1,598,176 |
| 2020 | 7,166 | 781 | 0% (0) | 16% | $1,273,752 |
| 2019 | 6,326 | 776 | 0% (0) | 14% | $917,697 |
| 2018 | 5,972 | 717 | 0% (0) | 15% | $823,402 |
| 2017 | 5,302 | 650 | 0% (0) | 19% | $733,026 |
| 2016 | 4,959 | 579 | 0% (0) | 24% | $728,186 |
| 2015 | 4,748 | 527 | 0% (0) | 28% | $619,730 |
| 2014 | 4,631 | 507 | 0% (0) | 30% | $536,865 |
| 2013 | 4,830 | 500 | None | None | $531,476 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 50 drugs
| Eliquis | 634 | $920,317 | $1,452 |
| Jardiance | 487 | $779,330 | $1,600 |
| Entresto | 142 | $247,617 | $1,744 |
| Repatha Sureclick | 97 | $109,342 | $1,127 |
| Praluent | 90 | $91,744 | $1,019 |
| Multaq | 60 | $88,858 | $1,481 |
| Xarelto | 51 | $66,334 | $1,301 |
| Ezetimibe | 762 | $42,936 | $56 |
| Atorvastatin | 1,329 | $18,473 | $14 |
| Losartan | 1,196 | $17,637 | $15 |
| Vascepa | 13 | $13,891 | $1,069 |
| Dofetilide | 19 | $10,705 | $563 |
| Rosuvastatin | 349 | $8,694 | $25 |
| Carvedilol | 506 | $8,635 | $17 |
| Amlodipine Besylate | 783 | $6,726 | $9 |
| Eplerenone | 54 | $6,510 | $121 |
| Spironolactone | 434 | $5,967 | $14 |
| Metoprolol | 258 | $5,270 | $20 |
| Diltiazem 24hr Er (Cd) | 78 | $5,157 | $66 |
| Spironolactone-Hctz | 65 | $2,825 | $43 |
| Irbesartan | 78 | $2,729 | $35 |
| Sotalol | 71 | $2,569 | $36 |
| Pravastatin | 127 | $2,525 | $20 |
| Olmesartan Medoxomil | 36 | $2,325 | $65 |
| Lisinopril | 200 | $2,291 | $11 |
| Amiodarone | 59 | $2,060 | $35 |
| Midodrine | 23 | $2,025 | $88 |
| Hydrochlorothiazide | 294 | $2,010 | $7 |
| Clopidogrel | 105 | $1,820 | $17 |
| Valsartan | 54 | $1,652 | $31 |
| Levothyroxine | 71 | $1,483 | $21 |
| Furosemide | 166 | $1,427 | $9 |
| Simvastatin | 82 | $995 | $12 |
| Sotalol Af | 16 | $966 | $60 |
| Metformin Hcl Er | 42 | $840 | $20 |
| Losartan-Hydrochlorothiazide | 45 | $833 | $19 |
| Digoxin | 26 | $827 | $32 |
| Valsartan-Hydrochlorothiazide | 17 | $726 | $43 |
| Olmesartan-Hydrochlorothiazide | 12 | $650 | $54 |
| Metformin | 45 | $606 | $13 |
| Flecainide Acetate | 15 | $579 | $39 |
| Enalapril Maleate | 16 | $543 | $34 |
| Torsemide | 18 | $467 | $26 |
| Pantoprazole | 25 | $390 | $16 |
| Allopurinol | 30 | $371 | $12 |
| Tamsulosin | 11 | $284 | $26 |
| Omeprazole | 18 | $211 | $12 |
| Atenolol | 11 | $205 | $19 |
| Benazepril | 23 | $193 | $8 |
| Triamterene-Hydrochlorothiazid | 12 | $91 | $8 |
2022: 55 drugs
| Eliquis | 592 | $779,854 | $1,317 |
| Jardiance | 328 | $539,524 | $1,645 |
| Entresto | 110 | $152,762 | $1,389 |
| Praluent | 79 | $76,009 | $962 |
| Repatha Sureclick | 91 | $68,170 | $749 |
| Multaq | 43 | $62,233 | $1,447 |
| Ezetimibe | 654 | $52,020 | $80 |
| Xarelto | 33 | $46,900 | $1,421 |
| Trulicity | 18 | $33,179 | $1,843 |
| Atorvastatin | 1,169 | $16,608 | $14 |
| Rosuvastatin | 305 | $15,541 | $51 |
| Vascepa | 16 | $14,412 | $901 |
| Losartan | 1,021 | $14,295 | $14 |
| Ozempic | 12 | $11,310 | $943 |
| Dofetilide | 20 | $7,528 | $376 |
| Eplerenone | 46 | $7,192 | $156 |
| Carvedilol | 441 | $7,159 | $16 |
| Spironolactone | 371 | $5,471 | $15 |
| Metoprolol | 220 | $5,224 | $24 |
| Amlodipine Besylate | 626 | $4,826 | $8 |
| Prasugrel | 17 | $4,399 | $259 |
| Diltiazem 24hr Er (Cd) | 73 | $3,882 | $53 |
| Pravastatin | 112 | $2,367 | $21 |
| Propafenone | 19 | $2,270 | $119 |
| Clopidogrel | 88 | $2,241 | $25 |
| Furosemide | 193 | $2,192 | $11 |
| Spironolactone-Hctz | 44 | $2,184 | $50 |
| Valsartan | 53 | $2,160 | $41 |
| Lisinopril | 226 | $1,992 | $9 |
| Irbesartan | 71 | $1,978 | $28 |
| Hydrochlorothiazide | 287 | $1,865 | $6 |
| Sotalol | 63 | $1,836 | $29 |
| Ezetimibe-Simvastatin | 17 | $1,734 | $102 |
| Olmesartan Medoxomil | 23 | $1,707 | $74 |
| Midodrine | 16 | $1,447 | $90 |
| Levothyroxine | 54 | $1,341 | $25 |
| Amiodarone | 49 | $1,273 | $26 |
| Digoxin | 32 | $1,242 | $39 |
| Simvastatin | 85 | $997 | $12 |
| Enalapril Maleate | 26 | $972 | $37 |
| Valsartan-Hydrochlorothiazide | 17 | $865 | $51 |
| Metformin Hcl Er | 51 | $854 | $17 |
| Flecainide Acetate | 16 | $849 | $53 |
| Losartan-Hydrochlorothiazide | 28 | $718 | $26 |
| Allopurinol | 29 | $481 | $17 |
| Metformin | 46 | $412 | $9 |
| Pantoprazole | 26 | $331 | $13 |
| Torsemide | 14 | $310 | $22 |
| Benazepril | 31 | $293 | $9 |
| Omeprazole | 26 | $270 | $10 |
| Famotidine | 11 | $201 | $18 |
| Metoprolol | 22 | $185 | $8 |
| Warfarin | 15 | $155 | $10 |
| Sertraline | 13 | $147 | $11 |
| Atenolol | 16 | $137 | $9 |
2021: 57 drugs
| Eliquis | 506 | $589,895 | $1,166 |
| Jardiance | 275 | $398,488 | $1,449 |
| Entresto | 79 | $116,334 | $1,473 |
| Praluent | 109 | $60,004 | $550 |
| Repatha Sureclick | 72 | $52,831 | $734 |
| Multaq | 40 | $51,075 | $1,277 |
| Ezetimibe | 616 | $42,861 | $70 |
| Xarelto | 36 | $41,814 | $1,161 |
| Vascepa | 35 | $24,081 | $688 |
| Atorvastatin | 1,104 | $19,496 | $18 |
| Farxiga | 15 | $19,187 | $1,279 |
| Trulicity | 11 | $18,336 | $1,667 |
| Losartan | 913 | $14,060 | $15 |
| Rosuvastatin | 255 | $10,952 | $43 |
| Dofetilide | 25 | $10,598 | $424 |
| Eplerenone | 48 | $7,299 | $152 |
| Carvedilol | 457 | $7,052 | $15 |
| Amlodipine Besylate | 546 | $5,526 | $10 |
| Spironolactone | 327 | $5,071 | $16 |
| Diltiazem 24hr Er (Cd) | 76 | $4,945 | $65 |
| Irbesartan | 65 | $4,154 | $64 |
| Metoprolol | 168 | $4,076 | $24 |
| Prasugrel | 16 | $3,792 | $237 |
| Propafenone | 28 | $3,765 | $134 |
| Valsartan | 64 | $3,396 | $53 |
| Spironolactone-Hctz | 47 | $2,395 | $51 |
| Furosemide | 210 | $2,373 | $11 |
| Pravastatin | 106 | $2,358 | $22 |
| Lisinopril | 223 | $2,099 | $9 |
| Hydrochlorothiazide | 259 | $1,874 | $7 |
| Valsartan-Hydrochlorothiazide | 17 | $1,860 | $109 |
| Ezetimibe-Simvastatin | 16 | $1,827 | $114 |
| Sotalol | 55 | $1,699 | $31 |
| Clopidogrel | 78 | $1,553 | $20 |
| Olmesartan Medoxomil | 15 | $1,334 | $89 |
| Levothyroxine | 45 | $1,289 | $29 |
| Amiodarone | 30 | $1,145 | $38 |
| Losartan-Hydrochlorothiazide | 35 | $1,049 | $30 |
| Digoxin | 28 | $1,046 | $37 |
| Simvastatin | 91 | $968 | $11 |
| Flecainide Acetate | 22 | $810 | $37 |
| Enalapril Maleate | 19 | $717 | $38 |
| Torsemide | 13 | $538 | $41 |
| Metformin Hcl Er | 53 | $520 | $10 |
| Allopurinol | 30 | $500 | $17 |
| Warfarin | 22 | $424 | $19 |
| Metformin | 43 | $382 | $9 |
| Nitroglycerin | 17 | $359 | $21 |
| Benazepril | 29 | $321 | $11 |
| Potassium Chloride | 14 | $289 | $21 |
| Pantoprazole | 11 | $283 | $26 |
| Atenolol | 19 | $173 | $9 |
| Omeprazole | 19 | $166 | $9 |
| Triamterene-Hydrochlorothiazid | 11 | $141 | $13 |
| Sertraline | 11 | $107 | $10 |
| Amoxicillin | 11 | $24 | $2 |
| Diazepam | 14 | $13 | $1 |
2020: 59 drugs
| Eliquis | 465 | $529,607 | $1,139 |
| Jardiance | 152 | $204,356 | $1,344 |
| Entresto | 60 | $88,933 | $1,482 |
| Praluent | 77 | $49,314 | $640 |
| Xarelto | 44 | $48,658 | $1,106 |
| Ezetimibe | 602 | $47,263 | $79 |
| Repatha Sureclick | 61 | $36,176 | $593 |
| Multaq | 13 | $25,151 | $1,935 |
| Atorvastatin | 1,032 | $21,798 | $21 |
| Pradaxa | 15 | $19,435 | $1,296 |
| Trulicity | 19 | $16,751 | $882 |
| Rosuvastatin | 214 | $13,234 | $62 |
| Losartan | 877 | $13,144 | $15 |
| Dofetilide | 24 | $8,826 | $368 |
| Vascepa | 17 | $8,327 | $490 |
| Eplerenone | 51 | $7,235 | $142 |
| Carvedilol Er | 11 | $7,169 | $652 |
| Repatha | 15 | $7,133 | $476 |
| Carvedilol | 436 | $6,040 | $14 |
| Prasugrel | 32 | $5,915 | $185 |
| Metoprolol | 182 | $5,293 | $29 |
| Spironolactone | 284 | $4,036 | $14 |
| Amlodipine Besylate | 466 | $4,019 | $9 |
| Irbesartan | 61 | $3,570 | $59 |
| Diltiazem 24hr Er (Cd) | 64 | $3,500 | $55 |
| Valsartan | 40 | $3,112 | $78 |
| Ezetimibe-Simvastatin | 16 | $2,938 | $184 |
| Pravastatin | 110 | $2,832 | $26 |
| Spironolactone-Hctz | 46 | $2,721 | $59 |
| Propafenone | 18 | $2,553 | $142 |
| Furosemide | 221 | $2,296 | $10 |
| Hydrochlorothiazide | 255 | $2,238 | $9 |
| Midodrine | 14 | $2,164 | $155 |
| Valsartan-Hydrochlorothiazide | 20 | $2,036 | $102 |
| Lisinopril | 202 | $1,994 | $10 |
| Sotalol | 50 | $1,701 | $34 |
| Losartan-Hydrochlorothiazide | 23 | $1,450 | $63 |
| Levothyroxine | 46 | $1,428 | $31 |
| Flecainide Acetate | 13 | $1,215 | $93 |
| Simvastatin | 120 | $1,191 | $10 |
| Clopidogrel | 60 | $1,159 | $19 |
| Fenofibrate | 11 | $988 | $90 |
| Digoxin | 30 | $955 | $32 |
| Amiodarone | 27 | $947 | $35 |
| Enalapril Maleate | 17 | $850 | $50 |
| Cartia Xt | 14 | $732 | $52 |
| Benazepril | 41 | $604 | $15 |
| Pantoprazole | 21 | $542 | $26 |
| Warfarin | 27 | $507 | $19 |
| Metolazone | 14 | $497 | $36 |
| Metformin Hcl Er | 37 | $454 | $12 |
| Potassium Chloride | 16 | $441 | $28 |
| Allopurinol | 27 | $383 | $14 |
| Metformin | 40 | $319 | $8 |
| Nitroglycerin | 13 | $268 | $21 |
| Atenolol | 24 | $247 | $10 |
| Omeprazole | 16 | $183 | $11 |
| Metoprolol | 15 | $104 | $7 |
| Sertraline | 11 | $82 | $7 |
2019: 56 drugs
| Eliquis | 376 | $418,733 | $1,114 |
| Praluent | 63 | $50,175 | $796 |
| Entresto | 45 | $47,663 | $1,059 |
| Xarelto | 39 | $41,900 | $1,074 |
| Ezetimibe | 495 | $38,233 | $77 |
| Jardiance | 29 | $37,889 | $1,307 |
| Repatha Sureclick | 45 | $36,101 | $802 |
| Pradaxa | 20 | $25,753 | $1,288 |
| Atorvastatin | 974 | $23,249 | $24 |
| Multaq | 15 | $19,779 | $1,319 |
| Dofetilide | 17 | $14,010 | $824 |
| Rosuvastatin | 173 | $13,136 | $76 |
| Losartan | 753 | $10,502 | $14 |
| Carvedilol | 475 | $7,578 | $16 |
| Prasugrel | 25 | $6,303 | $252 |
| Metoprolol | 139 | $5,612 | $40 |
| Eplerenone | 41 | $5,338 | $130 |
| Spironolactone-Hctz | 72 | $4,803 | $67 |
| Amlodipine Besylate | 404 | $4,358 | $11 |
| Spironolactone | 245 | $4,151 | $17 |
| Propafenone | 24 | $3,643 | $152 |
| Pravastatin | 113 | $3,511 | $31 |
| Diltiazem 24hr Er (Cd) | 73 | $3,491 | $48 |
| Lisinopril | 225 | $2,281 | $10 |
| Irbesartan | 52 | $2,174 | $42 |
| Hydrochlorothiazide | 216 | $2,122 | $10 |
| Furosemide | 209 | $2,101 | $10 |
| Sotalol | 41 | $1,700 | $41 |
| Valsartan | 36 | $1,662 | $46 |
| Cartia Xt | 23 | $1,592 | $69 |
| Digoxin | 28 | $1,581 | $56 |
| Flecainide Acetate | 13 | $1,408 | $108 |
| Midodrine | 14 | $1,273 | $91 |
| Levothyroxine | 41 | $1,234 | $30 |
| Simvastatin | 114 | $1,188 | $10 |
| Clopidogrel | 44 | $1,003 | $23 |
| Fenofibrate | 13 | $940 | $72 |
| Valsartan-Hydrochlorothiazide | 25 | $939 | $38 |
| Telmisartan | 11 | $890 | $81 |
| Dilt-Xr | 12 | $846 | $71 |
| Benazepril | 35 | $698 | $20 |
| Losartan-Hydrochlorothiazide | 24 | $675 | $28 |
| Enalapril Maleate | 12 | $604 | $50 |
| Metolazone | 17 | $569 | $33 |
| Metformin | 43 | $546 | $13 |
| Amiodarone | 14 | $539 | $38 |
| Pantoprazole | 27 | $397 | $15 |
| Toprol Xl | 12 | $392 | $33 |
| Allopurinol | 16 | $310 | $19 |
| Warfarin | 15 | $298 | $20 |
| Atenolol | 22 | $290 | $13 |
| Digox | 11 | $274 | $25 |
| Nitroglycerin | 13 | $256 | $20 |
| Omeprazole | 15 | $204 | $14 |
| Metoprolol | 13 | $155 | $12 |
| Diazepam | 11 | $21 | $2 |
2018: 55 drugs
| Eliquis | 340 | $337,983 | $994 |
| Xarelto | 65 | $54,546 | $839 |
| Praluent | 44 | $49,400 | $1,123 |
| Ezetimibe | 366 | $43,808 | $120 |
| Pradaxa | 35 | $39,084 | $1,117 |
| Entresto | 30 | $30,901 | $1,030 |
| Repatha Sureclick | 25 | $30,463 | $1,219 |
| Atorvastatin | 886 | $22,392 | $25 |
| Multaq | 17 | $19,807 | $1,165 |
| Prasugrel | 44 | $11,841 | $269 |
| Rosuvastatin | 164 | $10,873 | $66 |
| Dofetilide | 17 | $10,747 | $632 |
| Welchol | 13 | $10,646 | $819 |
| Brilinta | 15 | $9,499 | $633 |
| Carvedilol Er | 13 | $8,563 | $659 |
| Losartan | 622 | $7,850 | $13 |
| Carvedilol | 437 | $6,841 | $16 |
| Eplerenone | 37 | $6,648 | $180 |
| Metoprolol | 159 | $6,422 | $40 |
| Spironolactone-Hctz | 84 | $4,639 | $55 |
| Propafenone | 26 | $4,070 | $157 |
| Amlodipine Besylate | 386 | $3,792 | $10 |
| Pravastatin | 117 | $3,321 | $28 |
| Spironolactone | 197 | $3,261 | $17 |
| Diltiazem 24hr Er (Cd) | 66 | $3,039 | $46 |
| Cartia Xt | 47 | $2,609 | $56 |
| Valsartan | 72 | $2,555 | $35 |
| Digoxin | 27 | $2,063 | $76 |
| Furosemide | 223 | $1,994 | $9 |
| Simvastatin | 153 | $1,944 | $13 |
| Lisinopril | 226 | $1,935 | $9 |
| Irbesartan | 63 | $1,825 | $29 |
| Hydrochlorothiazide | 156 | $1,479 | $9 |
| Fenofibrate | 16 | $1,178 | $74 |
| Digox | 17 | $1,165 | $69 |
| Levothyroxine | 40 | $1,131 | $28 |
| Valsartan-Hydrochlorothiazide | 43 | $1,072 | $25 |
| Enalapril Maleate | 13 | $981 | $75 |
| Clopidogrel | 41 | $729 | $18 |
| Metolazone | 23 | $658 | $29 |
| Amlodipine Besylate-Benazepril | 19 | $617 | $32 |
| Sotalol | 23 | $564 | $25 |
| Amiodarone | 21 | $555 | $26 |
| Losartan-Hydrochlorothiazide | 24 | $495 | $21 |
| Toprol Xl | 11 | $479 | $44 |
| Allopurinol | 15 | $472 | $31 |
| Warfarin | 16 | $458 | $29 |
| Nitroglycerin | 25 | $453 | $18 |
| Metformin | 40 | $437 | $11 |
| Atenolol | 29 | $394 | $14 |
| Benazepril | 32 | $393 | $12 |
| Omeprazole | 22 | $381 | $17 |
| Ramipril | 12 | $366 | $30 |
| Pantoprazole | 28 | $316 | $11 |
| Metoprolol | 26 | $273 | $10 |
2017: 54 drugs
| Eliquis | 323 | $265,951 | $823 |
| Zetia | 94 | $63,728 | $678 |
| Xarelto | 75 | $60,504 | $807 |
| Ezetimibe | 166 | $46,585 | $281 |
| Pradaxa | 41 | $39,926 | $974 |
| Praluent | 27 | $31,289 | $1,159 |
| Welchol | 21 | $19,595 | $933 |
| Multaq | 19 | $18,390 | $968 |
| Atorvastatin | 802 | $18,322 | $23 |
| Effient | 16 | $14,941 | $934 |
| Rosuvastatin | 157 | $11,398 | $73 |
| Coreg Cr | 17 | $9,690 | $570 |
| Dofetilide | 12 | $7,673 | $639 |
| Metoprolol | 131 | $6,014 | $46 |
| Carvedilol | 426 | $5,681 | $13 |
| Eplerenone | 38 | $5,413 | $142 |
| Losartan | 458 | $4,856 | $11 |
| Spironolactone-Hctz | 78 | $4,655 | $60 |
| Olmesartan Medoxomil | 14 | $3,896 | $278 |
| Propafenone | 28 | $3,829 | $137 |
| Pravastatin | 106 | $3,577 | $34 |
| Spironolactone | 215 | $3,299 | $15 |
| Amlodipine Besylate | 308 | $2,822 | $9 |
| Valsartan | 76 | $2,717 | $36 |
| Cartia Xt | 55 | $2,394 | $44 |
| Fenofibrate | 19 | $2,232 | $117 |
| Lisinopril | 236 | $2,201 | $9 |
| Diltiazem 24hr Er | 61 | $2,175 | $36 |
| Digox | 17 | $1,720 | $101 |
| Furosemide | 188 | $1,503 | $8 |
| Simvastatin | 147 | $1,457 | $10 |
| Digoxin | 22 | $1,439 | $65 |
| Irbesartan | 40 | $1,118 | $28 |
| Levothyroxine | 32 | $1,074 | $34 |
| Hydrochlorothiazide | 107 | $1,041 | $10 |
| Clopidogrel | 48 | $983 | $20 |
| Enalapril Maleate | 11 | $658 | $60 |
| Sotalol | 23 | $604 | $26 |
| Amiodarone | 29 | $590 | $20 |
| Warfarin | 18 | $513 | $28 |
| Potassium Chloride | 25 | $472 | $19 |
| Valsartan-Hydrochlorothiazide | 27 | $469 | $17 |
| Metformin | 46 | $453 | $10 |
| Losartan-Hydrochlorothiazide | 21 | $429 | $20 |
| Metolazone | 18 | $366 | $20 |
| Atenolol | 38 | $353 | $9 |
| Benazepril | 26 | $346 | $13 |
| Ramipril | 11 | $313 | $28 |
| Torsemide | 11 | $310 | $28 |
| Metoprolol | 35 | $292 | $8 |
| Omeprazole | 19 | $237 | $12 |
| Amlodipine Besylate-Benazepril | 14 | $222 | $16 |
| Pantoprazole | 21 | $205 | $10 |
| Diazepam | 14 | $25 | $2 |
2016: 55 drugs
| Eliquis | 306 | $198,039 | $647 |
| Zetia | 165 | $101,050 | $612 |
| Xarelto | 85 | $71,009 | $835 |
| Crestor | 95 | $57,807 | $608 |
| Pradaxa | 62 | $56,093 | $905 |
| Welchol | 36 | $23,819 | $662 |
| Effient | 23 | $20,860 | $907 |
| Atorvastatin | 704 | $19,999 | $28 |
| Praluent | 14 | $16,030 | $1,145 |
| Coreg Cr | 24 | $9,839 | $410 |
| Vytorin | 11 | $7,615 | $692 |
| Rosuvastatin | 45 | $6,559 | $146 |
| Benicar | 13 | $5,956 | $458 |
| Carvedilol | 431 | $5,459 | $13 |
| Metoprolol | 119 | $5,189 | $44 |
| Valsartan | 56 | $4,787 | $85 |
| Losartan | 395 | $4,459 | $11 |
| Pravastatin | 109 | $3,776 | $35 |
| Eplerenone | 19 | $3,584 | $189 |
| Spironolactone | 214 | $3,386 | $16 |
| Colchicine | 12 | $3,340 | $278 |
| Spironolactone-Hctz | 60 | $3,222 | $54 |
| Digoxin | 55 | $2,766 | $50 |
| Propafenone | 24 | $2,670 | $111 |
| Diltiazem 24hr Er | 57 | $2,449 | $43 |
| Amlodipine Besylate | 238 | $2,334 | $10 |
| Lisinopril | 250 | $2,101 | $8 |
| Cartia Xt | 32 | $2,052 | $64 |
| Clopidogrel | 59 | $1,964 | $33 |
| Fenofibrate | 22 | $1,651 | $75 |
| Simvastatin | 145 | $1,530 | $11 |
| Digox | 32 | $1,490 | $47 |
| Furosemide | 165 | $1,221 | $7 |
| Levothyroxine | 39 | $1,198 | $31 |
| Irbesartan | 47 | $1,118 | $24 |
| Diltiazem 24hr Cd | 15 | $1,091 | $73 |
| Hydrochlorothiazide | 97 | $1,054 | $11 |
| Fenofibrate | 12 | $863 | $72 |
| Valsartan-Hydrochlorothiazide | 26 | $834 | $32 |
| Sotalol | 30 | $600 | $20 |
| Digitek | 11 | $524 | $48 |
| Amiodarone | 24 | $495 | $21 |
| Ramipril | 14 | $480 | $34 |
| Potassium Chloride | 15 | $464 | $31 |
| Atenolol | 32 | $372 | $12 |
| Midodrine | 13 | $371 | $29 |
| Losartan-Hydrochlorothiazide | 31 | $362 | $12 |
| Metoprolol | 47 | $359 | $8 |
| Omeprazole | 22 | $350 | $16 |
| Metformin | 34 | $330 | $10 |
| Benazepril | 21 | $312 | $15 |
| Warfarin | 12 | $268 | $22 |
| Fosinopril | 11 | $246 | $22 |
| Sotalol Af | 14 | $199 | $14 |
| Pantoprazole | 13 | $159 | $12 |
2015: 57 drugs
| Eliquis | 271 | $138,752 | $512 |
| Xarelto | 106 | $76,521 | $722 |
| Crestor | 160 | $71,498 | $447 |
| Pradaxa | 102 | $65,378 | $641 |
| Zetia | 103 | $49,684 | $482 |
| Welchol | 51 | $25,854 | $507 |
| Effient | 35 | $24,694 | $706 |
| Atorvastatin | 647 | $17,865 | $28 |
| Tikosyn | 12 | $11,067 | $922 |
| Coreg Cr | 18 | $11,016 | $612 |
| Benicar | 25 | $8,136 | $325 |
| Valsartan | 44 | $6,296 | $143 |
| Metoprolol | 121 | $5,508 | $46 |
| Carvedilol | 410 | $4,800 | $12 |
| Propafenone | 46 | $4,624 | $101 |
| Eplerenone | 24 | $4,575 | $191 |
| Spironolactone-Hctz | 80 | $3,966 | $50 |
| Propafenone Hcl Er | 12 | $3,547 | $296 |
| Pravastatin | 90 | $3,356 | $37 |
| Losartan | 346 | $3,287 | $9 |
| Digoxin | 55 | $3,069 | $56 |
| Fenofibrate | 20 | $2,832 | $142 |
| Amlodipine Besylate | 262 | $2,256 | $9 |
| Exforge | 12 | $2,141 | $178 |
| Cartia Xt | 38 | $2,041 | $54 |
| Clopidogrel | 76 | $1,791 | $24 |
| Spironolactone | 154 | $1,780 | $12 |
| Diltiazem 24hr Er | 44 | $1,774 | $40 |
| Digox | 46 | $1,500 | $33 |
| Simvastatin | 173 | $1,438 | $8 |
| Lisinopril | 179 | $1,403 | $8 |
| Irbesartan | 39 | $1,324 | $34 |
| Fenofibrate | 16 | $1,226 | $77 |
| Valsartan-Hydrochlorothiazide | 21 | $1,141 | $54 |
| Levothyroxine | 39 | $1,117 | $29 |
| Potassium Chloride | 19 | $943 | $50 |
| Furosemide | 141 | $887 | $6 |
| Hydrochlorothiazide | 112 | $828 | $7 |
| Ramipril | 13 | $639 | $49 |
| Digitek | 14 | $632 | $45 |
| Enalapril Maleate | 11 | $600 | $55 |
| Diltiazem Er | 13 | $573 | $44 |
| Metolazone | 14 | $558 | $40 |
| Amiodarone | 30 | $458 | $15 |
| Verapamil Er | 15 | $451 | $30 |
| Benazepril | 25 | $442 | $18 |
| Dilt-Xr | 11 | $398 | $36 |
| Metoprolol | 47 | $361 | $8 |
| Nitrostat | 18 | $360 | $20 |
| Sotalol | 20 | $352 | $18 |
| Fosinopril | 11 | $277 | $25 |
| Metformin | 26 | $263 | $10 |
| Losartan-Hydrochlorothiazide | 24 | $257 | $11 |
| Atenolol | 42 | $250 | $6 |
| Omeprazole | 14 | $161 | $11 |
| Lovastatin | 11 | $146 | $13 |
| Diazepam | 11 | $30 | $3 |
2014: 61 drugs
| Eliquis | 186 | $75,188 | $404 |
| Pradaxa | 144 | $72,531 | $504 |
| Xarelto | 118 | $71,074 | $602 |
| Crestor | 135 | $58,510 | $433 |
| Welchol | 55 | $29,667 | $539 |
| Zetia | 71 | $29,584 | $417 |
| Atorvastatin | 634 | $19,094 | $30 |
| Diovan | 51 | $12,891 | $253 |
| Effient | 29 | $12,773 | $440 |
| Tikosyn | 20 | $10,738 | $537 |
| Coreg Cr | 29 | $10,058 | $347 |
| Metoprolol | 138 | $6,898 | $50 |
| Fenofibrate | 33 | $6,290 | $191 |
| Carvedilol | 363 | $5,610 | $15 |
| Celebrex | 11 | $4,472 | $407 |
| Propafenone | 49 | $4,016 | $82 |
| Losartan | 262 | $3,851 | $15 |
| Vytorin | 11 | $3,642 | $331 |
| Valsartan | 15 | $3,328 | $222 |
| Spironolactone-Hctz | 70 | $3,312 | $47 |
| Colcrys | 15 | $3,232 | $215 |
| Digoxin | 49 | $3,068 | $63 |
| Eplerenone | 20 | $2,919 | $146 |
| Clopidogrel | 70 | $2,868 | $41 |
| Diltiazem 24hr Er | 58 | $2,819 | $49 |
| Amlodipine Besylate | 234 | $2,733 | $12 |
| Valsartan-Hydrochlorothiazide | 32 | $2,720 | $85 |
| Benicar | 11 | $2,669 | $243 |
| Digox | 59 | $2,627 | $45 |
| Irbesartan | 47 | $2,468 | $53 |
| Pravastatin | 73 | $2,433 | $33 |
| Spironolactone | 162 | $2,049 | $13 |
| Simvastatin | 182 | $1,946 | $11 |
| Exforge | 12 | $1,817 | $151 |
| Lisinopril | 182 | $1,436 | $8 |
| Diltiazem 24hr Cd | 18 | $1,291 | $72 |
| Ramipril | 21 | $1,191 | $57 |
| Amlodipine Besylate-Benazepril | 12 | $1,181 | $98 |
| Hydrochlorothiazide | 108 | $1,013 | $9 |
| Levothyroxine | 33 | $914 | $28 |
| Toprol Xl | 17 | $914 | $54 |
| Diltiazem Er | 26 | $863 | $33 |
| Cartia Xt | 14 | $837 | $60 |
| Furosemide | 141 | $830 | $6 |
| Amiodarone | 34 | $799 | $23 |
| Quinapril | 15 | $673 | $45 |
| Sotalol | 22 | $592 | $27 |
| Omeprazole | 21 | $581 | $28 |
| Potassium Chloride | 15 | $504 | $34 |
| Metolazone | 12 | $494 | $41 |
| Metformin | 30 | $386 | $13 |
| Verapamil Er | 14 | $385 | $27 |
| Lovastatin | 16 | $381 | $24 |
| Fosinopril | 23 | $378 | $16 |
| Metoprolol | 53 | $337 | $6 |
| Losartan-Hydrochlorothiazide | 24 | $292 | $12 |
| Warfarin | 15 | $288 | $19 |
| Benazepril | 14 | $273 | $20 |
| Nitrostat | 18 | $251 | $14 |
| Atenolol | 31 | $217 | $7 |
| Diazepam | 22 | $54 | $2 |
2013: 59 drugs
| Pradaxa | 191 | $79,763 | $418 |
| Xarelto | 169 | $79,322 | $469 |
| Crestor | 193 | $62,266 | $323 |
| Atorvastatin | 570 | $29,307 | $51 |
| Zetia | 60 | $23,958 | $399 |
| Welchol | 52 | $20,541 | $395 |
| Diovan | 70 | $19,967 | $285 |
| Tikosyn | 34 | $15,850 | $466 |
| Eliquis | 31 | $14,405 | $465 |
| Niaspan | 41 | $12,987 | $317 |
| Fenofibrate | 46 | $10,989 | $239 |
| Vytorin | 43 | $10,651 | $248 |
| Coreg Cr | 30 | $9,685 | $323 |
| Carvedilol | 354 | $7,297 | $21 |
| Metoprolol | 137 | $7,041 | $51 |
| Lovaza | 15 | $6,651 | $443 |
| Propafenone | 47 | $6,046 | $129 |
| Clopidogrel | 100 | $5,928 | $59 |
| Losartan | 218 | $5,096 | $23 |
| Celebrex | 13 | $4,181 | $322 |
| Diltiazem 24hr Er | 82 | $4,128 | $50 |
| Valsartan-Hydrochlorothiazide | 32 | $3,849 | $120 |
| Exforge | 14 | $3,425 | $245 |
| Eplerenone | 27 | $3,387 | $125 |
| Simvastatin | 231 | $3,055 | $13 |
| Amlodipine Besylate | 215 | $3,040 | $14 |
| Spironolactone | 193 | $2,741 | $14 |
| Irbesartan | 35 | $2,203 | $63 |
| Spironolactone-Hctz | 73 | $2,150 | $29 |
| Diltiazem Er | 45 | $2,059 | $46 |
| Lisinopril | 214 | $1,926 | $9 |
| Amlodipine Besylate-Benazepril | 13 | $1,917 | $147 |
| Pravastatin | 64 | $1,509 | $24 |
| Omeprazole | 38 | $1,298 | $34 |
| Toprol Xl | 19 | $1,232 | $65 |
| Disopyramide Phosphate | 13 | $1,177 | $91 |
| Furosemide | 166 | $1,155 | $7 |
| Hydrochlorothiazide | 91 | $965 | $11 |
| Cartia Xt | 14 | $895 | $64 |
| Sotalol | 26 | $850 | $33 |
| Quinapril | 25 | $830 | $33 |
| Ramipril | 20 | $828 | $41 |
| Diltiazem 24hr Cd | 17 | $813 | $48 |
| Losartan-Hydrochlorothiazide | 40 | $731 | $18 |
| Digox | 65 | $701 | $11 |
| Fosinopril | 36 | $668 | $19 |
| Metolazone | 16 | $644 | $40 |
| Amiodarone | 22 | $555 | $25 |
| Warfarin | 34 | $541 | $16 |
| Lovastatin | 17 | $503 | $30 |
| Levothyroxine | 26 | $398 | $15 |
| Metformin | 26 | $378 | $15 |
| Digoxin | 24 | $338 | $14 |
| Triamterene-Hctz | 19 | $327 | $17 |
| Metoprolol | 42 | $321 | $8 |
| Atenolol | 31 | $292 | $9 |
| Potassium Chloride | 17 | $291 | $17 |
| Benazepril | 12 | $249 | $21 |
| Isosorbide Mononitrate Er | 11 | $218 | $20 |
Money from drug and device companies
$551 in 2025
| 2025 | 4 | 5 | None | $551 |
| 2024 | 1 | 1 | None | $25 |
| 2023 | 1 | 1 | None | $241 |
| 2021 | 1 | 1 | None | $12 |
| 2020 | 13 | 29 | None | $731 |
| 2019 | 16 | 158 | None | $2,612 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AtriCure | Epi-Sense Guided Coagulation System With Visitrax | $269 | 2 payments
|
| Medtronic | Aurora Ev-Icd Mri Surescan | $164 | 1 payment
|
| W. L. Gore & Associates | Excluder Conformable Aaa Endoprosthesis With Active Control | $98 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $20 | 1 payment
|
See all 5 published payments
| W. L. Gore & Associates | Meals · 2025-12-02 | Excluder Conformable Aaa Endoprosthesis With Active Control | $98 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-24 | Camzyos | $20 |
| AtriCure | Meals · 2025-07-23 | Epi-Sense Guided Coagulation System With Visitrax | $164 |
| AtriCure | Meals · 2025-05-27 | Epi-Sense Guided Coagulation System With Visitrax | $106 |
| Medtronic | Meals · 2025-05-19 | Aurora Ev-Icd Mri Surescan | $164 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $25
| E.R. Squibb & Sons L.L.C. | Eliquis | $25 | 1 payment
|
2023: $241
| Ablacon | None | $241 | 1 payment
|
2021: $12
| Amgen | Corlanor | $12 | 1 payment
|
2020: $731
| Medicure Pharma | Heart Failure Device. | $228 | 1 payment
|
| Pfizer | Eliquis | $121 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $90 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $68 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $53 | 3 payments
|
| Abbott Laboratories | Confirm Rx | $34 | 1 payment
|
| Abiomed | Impella | $24 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $22 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $20 | 1 payment
|
| Amgen | Corlanor | $19 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $19 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $19 | 1 payment
|
| Novo Nordisk | Ozempic | $14 | 1 payment
|
2019: $2,612
| Amgen | Repatha | $587 | 21 payments
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $325 | 32 payments
|
| Sanofi-Aventis U.S. | Praluent | $267 | 13 payments
|
| Janssen Pharmaceuticals | Xarelto | $266 | 19 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $240 | 13 payments
|
| Pfizer | Vyndaqel | $195 | 19 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $168 | 10 payments
|
| Regeneron Healthcare Solutions | Praluent | $161 | 9 payments
|
| Novartis Pharmaceuticals | Entresto | $148 | 7 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $74 | 3 payments
|
| Boston Scientific | Watchman | $53 | 3 payments
|
| Daiichi Sankyo | Injectafer | $40 | 2 payments
|
| Amarin Pharma | Vascepa | $29 | 2 payments
|
| Novo Nordisk | Ozempic | $24 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $20 | 1 payment
|
| Medtronic Vascular | Venaseal | $16 | 1 payment
|
Professional record
- NPI
- 1346274602
- Licence
- CA G65711California G65711: Current · expires 2027-03-31
- Trained
- University of Utah School of Medicine, 1986
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Federal specialty code 207RI0011X (207RI0011X); Federal specialty code 207UN0901X (207UN0901X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-07-10
- NPI last updated
- 2020-05-28
- NPI record certified
- 2020-05-28
This is when the NPI record was last certified, not a medical board exam.